Nasdaq:US$14.68 (+0.25) | HKEX:HK$23.26 (+0.38) | AIM:£2.20 (+0.01)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)